Abstract
Radionuclide therapy with 223 Ra-dichloride is used to treat bone metastases and to improve the quality of life of patients with metastatic castration-resistant prostate cancer. At the present time there is no reliable data on the biodistribution of the 223 Ra-dichloride in the patient body. The aim of this study was to assess absorbed, equivalent doses in radiosensitive organs and tissues and effective dose from internal exposure for patients with metastatic castration-resistant prostate cancer treated with 223 Ra-dichloride. Internal doses from 223 Ra-dichloride were calculated for a chamber model specific for patients with metastatic castration-resistant prostate cancer. This model consists of 8 chambers (blood plasma, two chambers describing bone tissue, small intestine, upper large intestine, lower large intestine, feces and the rest of the body). Time-integrated activities were calculated using the SAAM II v2.3 software. The IDAC-Dose 2.1 software was used to calculate the absorbed doses. The highest absorbed doses in organs and equivalent doses were determined for the bone surface and red bone marrow. The absorbed dose from a-radiation in the bone surface for a set of six therapeutic procedures with 223 Ra-dichloride was estimated as 1 Gy; in the red bone marrow — 0.14 Gy. However, the approach used does not specifically consider accumulation of the radiopharmaceutical in metastases, which can lead to a significant overestimation of the absorbed dose in the healthy part of the bone surface and red bone marrow.
Highlights
Рак предстательной железы является наиболее часто встречающимся онкологическим заболеванием мочеполовой системы у мужчин [1]
The aim of this study was to assess absorbed, equivalent doses in radiosensitive organs and tissues and effective dose from internal exposure for patients with metastatic castration-resistant prostate cancer treated with 223Ra-dichloride
Internal doses from 223Ra-dichloride were calculated for a chamber model specific for patients with metastatic castration-resistant prostate cancer
Summary
Целью данной работы являлась оценка поглощенных и эквивалентных доз в радиочувствительных органах и тканях от внутреннего облучения для пациентов с метастатическим кастрационно-резистентным раком предстательной железы при терапии 223Ra-дихлоридом. Дозы внутреннего облучения от 223Ra-дихлорида были рассчитаны для камерной модели пациентов с метастатическим кастрационно-резистентным раком предстательной железы. Для радиационной защиты пациентов при планировании курса радионуклидной терапии с использованием 223Ra-дихлорида необходимо разработать методы оценки поглощенных доз в органе-мишени и в остальных радиочувствительных органах и тканях. Для этого необходимо разработать методику оценки поглощенных доз на основании моделей биораспределения РФП в организме пациентов, что особенно актуально на этапе клинических испытаний, когда экспериментальные данные по пациентам отсутствуют. Цель исследования – оценка поглощенных доз в радиочувствительных органах и тканях от внутреннего облучения для пациентов с мКРРПЖ при терапии 223Raдихлоридом, в рамках которой были определены:.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
